Previous close | 0.8000 |
Open | 0.8000 |
Bid | 0.0000 |
Ask | 3.6000 |
Strike | 115.00 |
Expiry date | 2024-10-18 |
Day's range | 0.8000 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | 14 |
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved patient worry, health distress and stigm
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE:LLY) shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Tirzepatide is a key ingredient in popular Mounjaro for diabetes and Zepbound for weight loss. Other companies working on MASH candida
CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madriga